Michel Joly is Vice President of Gilead Patient Solutions within Gilead Sciences, the entity responsible for medicine access programs in 140 resource‑limited countries.

He holds a Doctorate in Pharmacy and is a former resident of the Paris public hospitals, with a specialization in pharmacology. He is a member of the French Academy of Pharmacy. He began his career in research in the United States before joining the pharmaceutical industry.

After holding positions at GSK, Roche, Sanofi, and Novartis, he joined Gilead Sciences in 2013, where he was appointed President of the French affiliate.

He has held responsibilities in France and internationally in the areas of commercial operations, communications, and market access, where he contributed to the implementation of the early access reform in France, in connection with the medicine access issues currently addressed by Gilead Patient Solutions.